Disc Medicine (IRON) Gains from Investment Securities (2020 - 2026)
Disc Medicine (IRON) reported Gains from Investment Securities of $12000.0 for Q1 2026, up 180.0% year-over-year from $4285.7 in Q1 2025, and down 99.96% on a QoQ basis from $30.2 million in Q4 2025.
Disc Medicine (IRON) has 7 years of Gains from Investment Securities data on file, last reported at $12000.0 in Q1 2026.
- Quarterly Gains from Investment Securities rose 180.0% year-over-year to $12000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $30.2 million (up 321.93% YoY) and the FY2025 annual result came in at $3.3 million, up 13.9% from the prior year.
- Gains from Investment Securities declined to $12000.0 in Q1 2026 per IRON's latest filing, from $30.2 million in the prior quarter.
- Across five years, Gains from Investment Securities topped out at $30.2 million in Q4 2025 and bottomed at -$15000.0 in Q4 2024.
- The 5-year median for Gains from Investment Securities is $840241.0 (2022), against an average of $3.5 million.
- Peak annual rise in Gains from Investment Securities reached 201433.33% in 2025, while the deepest fall reached 148.51% in 2025.
- Tracing IRON's Gains from Investment Securities over 5 years: stood at $1.2 million in 2022, then surged by 520.49% to $7.2 million in 2023, then sank by 100.21% to -$15000.0 in 2024, then soared by 201433.33% to $30.2 million in 2025, then slumped by 99.96% to $12000.0 in 2026.
- Per Business Quant, the three latest IRON Gains from Investment Securities figures stand at $12000.0 (Q1 2026), $30.2 million (Q4 2025), and $15000.0 (Q2 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Disc Medicine | 2.76 Bn | 2.03 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 12,000.00 |
| Mar 31, 2026 | 12,000.00 |
| Dec 31, 2025 | 30.20 Mn |
| Dec 31, 2025 | 30.20 Mn |
| Jun 30, 2025 | 15,000.00 |
| Jun 30, 2025 | 15,000.00 |
| Mar 31, 2025 | -15,000.00 |
| Mar 31, 2025 | -15,000.00 |
| Dec 31, 2024 | -15,000.00 |
| Dec 31, 2024 | -15,000.00 |
| Sep 30, 2024 | 2.97 Mn |
| Sep 30, 2024 | 2.97 Mn |
| Jun 30, 2024 | 696,533.00 |
| Jun 30, 2024 | 696,533.00 |
| Mar 31, 2024 | 30,924.00 |
| Mar 31, 2024 | 30,924.00 |
| Dec 31, 2023 | 7.19 Mn |
| Dec 31, 2023 | 7.19 Mn |
| Sep 30, 2023 | 2.56 Mn |
| Sep 30, 2023 | 2.56 Mn |
| Jun 30, 2023 | 70,430.00 |
| Jun 30, 2023 | 70,430.00 |
| Mar 31, 2023 | 2.53 Mn |
| Mar 31, 2023 | 2.53 Mn |
| Sep 30, 2022 | 1.16 Mn |
| Sep 30, 2022 | 1.16 Mn |
| Jun 30, 2022 | 983,949.00 |
| Jun 30, 2022 | 983,949.00 |
| Dec 31, 2021 | 1.46 Mn |
| Dec 31, 2021 | 1.46 Mn |
| Sep 30, 2021 | 1.31 Mn |
| Sep 30, 2021 | 1.31 Mn |
| Jun 30, 2021 | 983,949.00 |
| Jun 30, 2021 | 983,949.00 |
| Mar 31, 2021 | 2.30 Mn |
| Mar 31, 2021 | 2.30 Mn |
| Dec 31, 2020 | 120.75 Mn |
| Dec 31, 2020 | 120.75 Mn |
| Sep 30, 2020 | 8,000.00 |
| Sep 30, 2020 | 8,000.00 |
| Mar 31, 2020 | -2,000.00 |
| Mar 31, 2020 | -2,000.00 |